Home › Research › Down syndrome and Alzheimer's
Down syndrome, increased risk of dementia and lipid disturbances
Kłosowska A, Ćwiklińska A, Kuchta A, Berlińska A, Jankowski M, Wierzba J.. Developmental period medicine, 2017-01-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Down syndrome (DS) is the most common chromosomal aberration and genetically determined cause of intellectual disability. DS patients often present with some congenital defects and chronic diseases, including early onset dementia, which affects 70% of DS patients over 55 years of age and has a clinical presentation similar to Alzheimer disease (AD). The symptoms of DS originate from excessive genetic material within the "critical region" of the 21st chromosome. The "critical region" encompasses genes potentially associated with increase risk of dementia, e.g. the APP gene (amyloid beta precursor protein) which leads to excessive amyloid beta production. Post-mortem studies of DS patients' brains revealed diffuse deposition of the insoluble form of amyloid beta (Aβ), which is a characteristic feature of AD. Moreover, those changes were commonly observed in subjects > 31 years old. The pathomechanisms of AD have not been fully elucidated and scientists are still searching for new risk factors that may contribute to the development of this common illness. Recent research proved that lipid disturbance, especially disorders in the metabolism of HDL (high density lipoprotein) may play a crucial role in this pathogenic process. There are many studies examining lipid and lipoprotein concentration in the DS population, but up to now there are insufficient studies comparing these parameters with memory impairment, which may be a useful model for better understanding of the dementia pathomechanism.
What this study adds
Evidence grade: Low
This is a narrative review. This review explains that the chromosome 21 critical region includes the APP gene, leading to excessive amyloid beta production, and that post-mortem Down syndrome brains show diffuse amyloid beta deposits commonly after age 31. It also notes that lipid disturbances, especially in HDL metabolism, are being studied as possible risk factors, but no treatment is tested.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Kłosowska, A., Ćwiklińska, A., Kuchta, A., Berlińska, A., Jankowski, M., & Wierzba, J. (2017). Down syndrome, increased risk of dementia and lipid disturbances. Developmental period medicine.
Vancouver
Kłosowska A, Ćwiklińska A, Kuchta A, Berlińska A, Jankowski M, Wierzba J. Down syndrome, increased risk of dementia and lipid disturbances. Developmental period medicine. 2017. PMID: 28551695.
BibTeX
@article{klosowska2017-28551695,
author = {Kłosowska, A. and Ćwiklińska, A. and Kuchta, A. and Berlińska, A. and Jankowski, M. and Wierzba, J.},
title = {{Down syndrome, increased risk of dementia and lipid disturbances}},
journal = {Developmental period medicine},
year = {2017},
pmid = {28551695}
}
Built from the record alzhub holds for this paper, not looked up. This record has no DOI, so the citation leaves it out. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The "critical region" encompasses genes potentially associated with increase risk of dementia, e.g. the APP gene (amyloid beta precursor protein) which leads to excessive amyloid beta production.
- Post-mortem studies of DS patients' brains revealed diffuse deposition of the insoluble form of amyloid beta (Aβ), which is a characteristic feature of AD.
Why it matters
This review explains that the chromosome 21 critical region includes the APP gene, leading to excessive amyloid beta production, and that post-mortem Down syndrome brains show diffuse amyloid beta deposits commonly after age 31. It also notes that lipid disturbances, especially in HDL metabolism, are being studied as possible risk factors, but no treatment is tested.
Study details
- Evidence strengthLow
How this study scored 30/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, so that was left out: it earned 29 of the 96 points we could judge it on, which is 30 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Developmental period medicine) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2017 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 5 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.5 citations a year over 11 year(s) since 2017 |
| Impact for its field and year | 1 / 6 | Cited 0.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Jolanta Wierzba: h-index 26 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Gdańsk Medical University: institution h-index 365 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 28551695) |
| Free to read | 2 / 2 | Free to read |
| Points | 29 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 29 of the 96 points we could judge it on is 30 out of 100. |
| Total | 30 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Down syndrome and Alzheimer's from nearby years
Also tagged “down”
527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.